Protocol 46 Inc.

ST. PAUL, MN · Founded 2018 · CIK 0001773597 · Biotech · Defunct

Micelle-engineered natural compound delivery system

protocol.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$410K
2 Form D · Oct 2019
84 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$410,274
Private capital raisedForm D · SEC$282,468
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1884Biosplice Therapeutics——
1885Krystal Biotech, Inc.—$11M
1886SANOSTEM GLOBAL, LLC—$3.5M
1887Protocol 46 Inc.—$410K
1888RETROVIROX, INC.——
1889Cotinga Pharmaceuticals Inc.—$3.0M
1890Antlia Bioscience, Inc.—$6.9M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Eric EbnerDirector · Executive Officer
  • Jason LivingstonDirector
  • Scott SchueDirector · Executive Officer
  • Ann SennDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.